Gw Henssler & Associates 13F: Cuts Merck (MRK) Stake by $597K
Key Points
- Gw Henssler reduced its holdings in Merck by 4,110 shares, now holding 175,274 shares valued at approximately $25.5 million.
- Merck's stock recently traded around $140.61, down about 3.2% from its closing price of $145.27 on October 23, 2026.
- The fund's stake in Merck accounts for 3.36% of its total reported value of $758.9 million, ranking it 12th among the fund's 224 positions.
Get Merck & Co. text alerts
We text you when insiders, Congress, analysts or big funds move on $MRK.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Merck & Co., Inc. alert may contain errors. Disclosures
On October 26, 2026, Gw Henssler & Associates trimmed its position in Merck & Co., Inc. (MRK) by 4,110 shares, reducing its total to 175,274 shares.
Where Merck Fits in Gw Henssler's Portfolio
The stake in Merck now represents 3.36% of Gw Henssler's total reported portfolio of $758.9 million, ranking it 12th among the fund's 224 holdings.
Other Institutional Activity in Merck
Several other funds have also adjusted their positions in Merck recently. Midwest Trust reduced its stake by 40,864 shares, ending with 697,609 shares worth about $101.4 million. Smith Chas P & Associates Pa Cpas cut its holdings by 6,761 shares, now holding 352,837 shares valued at approximately $51.5 million. Sumitomo Mitsui DS Asset Management Company decreased its position by 64,996 shares, bringing its total to 629,819 shares worth around $91.5 million.
Merck & Co., Inc. Stock Down 4.5%
Merck's shares recently traded at around $140.61, which is below its closing price of $145.27 on October 23, 2026. This indicates a decline of about 3.2% since the filing date, suggesting the stock is under some pressure.
Recent Earnings
Merck reported trailing twelve-month revenue of approximately $66.6 billion, with an EPS of $1.24. The next earnings report is scheduled for October 29, 2026, which may provide further insights into the company's performance.
Dividend
Merck pays an annual dividend rate of $3.40 per share, which reflects a high payout ratio of 266.7%. This indicates a strong commitment to returning value to shareholders.
Insider Buying and Selling at Merck & Co., Inc.
Several insiders have sold shares recently, including Chirfi Guindo, who sold 15,000 shares at an average price of $131 on August 6, 2026. This was followed by General Counsel Jennifer L. Zachary, who sold 80,315 shares at $133.46 on August 12, 2026.
Analysts Set New Price Targets
On October 26, 2026, Barclays maintained an Overweight rating on Merck with a new price target of $180, up from $150. Meanwhile, Cantor Fitzgerald and Citigroup both maintained Neutral ratings with price targets of $145.
About Merck
Merck & Co., Inc. is a global healthcare company based in Rahway, NJ, that develops and produces a wide range of pharmaceuticals. Its products include vaccines and treatments for various health conditions, such as Keytruda and Gardasil.
Bottom Line
Investors should watch for Merck's upcoming earnings report on October 29, 2026, as well as any further changes in institutional holdings. The recent adjustments by Gw Henssler and other funds may indicate shifting sentiment toward the stock.
Source: Gw Henssler & Associates's 13F filing on $MRK (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts